Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Driehaus Capital Management LLC

Driehaus Capital Management LLC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 370,661 shares of the medical equipment provider's stock after purchasing an additional 23,036 shares during the period. Driehaus Capital Management LLC owned about 0.53% of Lantheus worth $33,159,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the 3rd quarter valued at about $25,000. Kestra Investment Management LLC bought a new stake in Lantheus in the 4th quarter worth approximately $27,000. Summit Securities Group LLC bought a new position in Lantheus in the fourth quarter valued at about $37,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, World Investment Advisors LLC bought a new position in Lantheus in the third quarter worth approximately $60,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Down 2.7%

LNTH traded down $2.22 during midday trading on Monday, hitting $79.52. 2,167,057 shares of the company traded hands, compared to its average volume of 973,734. Lantheus Holdings, Inc. has a 52-week low of $75.00 and a 52-week high of $126.89. The business has a 50 day simple moving average of $99.15 and a two-hundred day simple moving average of $93.92. The company has a market capitalization of $5.45 billion, a price-to-earnings ratio of 13.23 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same period in the prior year, the company posted $1.69 EPS. The firm's revenue was up .8% on a year-over-year basis. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday. Finally, Truist Financial decreased their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.